Introduction
CD8+ cytolytic T cells have the unique potential to destroy virus infected cells and cancer cells. Cytolytic T cells are typically elicited against antigens present in the cytosol, which are processed by the proteasome and loaded onto nascent major histocompatibility class I (MHCI) complexes for presentation to CD8+ T cells. Vaccines based on recombinant protein antigens fail to access this cytosolic route of antigen processing and thereby yield poor cytolytic T cell responses. Conversely, nucleic acid based vaccines display a high potential to elicit cytolytic T cells, provided they support the expression of adequate amounts of antigen in the cytosol of dendritic cells (DCs), the most potent antigen presenting cells. Within the field of nucleic acid based vaccination, mRNA has now outcompeted To date, the mRNA delivery field has been heavily dominated by lipid-based systems. Reports on the use of nonlipid carriers for mRNA delivery in contrast are rare in the context of mRNA vaccination. This paper describes the potential of a cell-penetrating peptide containing the amphipathic RALA motif to deliver antigen-encoding mRNA to the immune system. RALA condenses mRNA into nanocomplexes that display acidic pH-dependent membrane disruptive properties. RALA mRNA nanocomplexes enable mRNA escape from endosomes and thereby allow expression of mRNA inside the dendritic cell cytosol. Strikingly, RALA mRNA nanocomplexes containing pseudouridine and 5-methylcytidine modified mRNA elicit potent cytolytic T cell responses against the antigenic mRNA cargo and show superior efficacy in doing so when compared to RALA mRNA nanocomplexes containing unmodified mRNA. RALA's unique sequence and structural organization are vital to act as mRNA vaccine vehicle, as arginine-rich peptide variants that lack the RALA motif show reduced mRNA complexation, impaired cellular uptake and lose the ability to transfect dendritic cells in vitro and to evoke T cell immunity in vivo.
plasmid DNA (pDNA) as the molecule of choice to deliver antigenic information due to its superior safety profile, its higher capacity to transfect nondividing cells, and its amenability to good manufacturing practice production. [1] Over the past years, preclinical and clinical studies have highlighted the potential of antigen-encoding mRNA to elicit T cell immunity upon intradermal [2] and intranodal [3] immunization. Nonetheless, these studies have also unmasked the limitations of naked mRNA vaccines and have emphasized the necessity to develop formulation strategies that can improve the potency of current mRNA vaccines. Packing the vaccine mRNA into nanoparticulate carriers constitutes an interesting avenue to achieve this goal as nanocarriers can protect the mRNA from fast degradation as well as selectively target DCs. To date, the mRNA delivery field has been heavily dominated by lipid based systems. [4] Reports on the use of nonlipid carriers for mRNA delivery in contrast are scarce. Moreover, virtually all polymeric carriers have been developed to deliver pDNA or small interfering RNA (siRNA) and perform very poor in the context of mRNA vaccination. [5] Protamine might constitute an exception to this rule, as protamine complexed mRNA has been demonstrated to evoke T cell responses upon intradermal administration. Nonetheless, expression levels of protamine complexed mRNA are extremely low. Curevac has tackled the low expression levels of protamine complexed mRNA through development of a two component mRNA vaccine, in which a noncomplexed, sequence optimized mRNA mediates antigen expression and protamine complexed mRNA mainly acts as adjuvant. [6] This failure of cationic polymers to deliver mRNA has been attributed to a too stringent binding of the mRNA to the cationic polymer along with an ineffective endosome-to-cytosol translocation. In a pioneering paper, Bettinger et al. demonstrated that the use of low molecular weight cationic polymers diminishes the strength of interaction between carrier and mRNA to such an extent that efficient mRNA expression can be achieved, provided an endosome disrupting agent is added. [7] Carriers suited for mRNA vaccination thereby should meet two major requirements. First, they need to bind mRNA with such strength that nanocomplexes are formed but ribosomal binding upon cytosolic delivery is not compromised. Second, they need to be endowed with endosome disrupting properties to translocate their mRNA cargo to the cytosol. Based on these premises, we speculated that cationic cell-penetrating peptides (CPPs) might constitute excellent vehicles for mRNA delivery as they combine lower charge densities with excellent membrane disruptive abilities. CPPs have been intensively exploited to deliver drugs, proteins, pDNA, and siRNA to the cellular cytosol [8] but have remained remarkably unexplored to deliver mRNA. Within the broad variety of CPPs, peptides containing the amphipathic RALA motif have emerged as particularly promising for systemic delivery of pDNA and siRNA because they selectively attack endosomal membranes and thereby display reduced toxicity. [9] In this study, we have explored the potential of RALA to deliver antigen-encoding mRNA to the immune system. RALA condensed mRNA into nanocomplexes that displayed pHdependent membrane disruptive properties and efficiently translocated their mRNA cargo from endocytic vesicles to the cytosol. RALA mRNA nanocomplexes supported antigen specific T cell proliferation in vivo. Strikingly, upon complexation to RALA, pseudouridine and 5-methylcytidine modified mRNA showed superior efficacy in instigating cytolytic T cell responses compared to nonmodified mRNA. Arginine rich peptide variants that lacked the amphipathic motif completely lost the ability to transfect DCs in vitro and to evoke T cell immunity in vivo, stressing the importance of the RALA sequence.
Results

Characterization of RALA mRNA Nanocomplexes
The sequence and secondary structure of RALA are shown in Figure 1A . At acidic pH, RALA displays an amphipathic α-helical structure with all hydrophilic arginine residues facing one side and all hydrophobic leucine residues facing the other side. This amphipathic organization enables RALA to complex nucleic acids electrostatically and to intercalate into endosomal membranes. [9] To address the capacity of RALA to condense mRNA into particles, we mixed increasing amounts of RALA with a fixed amount of mRNA and determined particle size by dynamic light scattering and particle ζ-potential by electrophoretic mobility measurements. The amount of peptide to mRNA is indicated by the N/P ratio and represents the molar ratio of positively charged nitrogen atoms in the peptide to negatively charged phosphates in the mRNA backbone. At N/P 1, a mean hydrodynamic diameter of 144 nm was measured, while at higher N/P ratios, the hydrodynamic diameter decreased to 89 nm (N/P 5) and 91 nm (N/P 10) ( Figure 1B) . The ζ-potential shifted from a negative value of −6.6 at N/P 1 to, respectively, +14.6 and +26.3 at N/P 5 and at N/P 10, in line with an increasing amount of RALA incorporated into the complexes at higher N/P ratios ( Figure 1C ). Nanoparticle formation was confirmed by transmission electron microscopy (TEM) ( Figure 1D ). The amount of mRNA incorporated into the RALA-mRNA nanocomplexes increased with increasing N/P ratios, ranging from a mere 5% at N/P 1, up to 88% at N/P 10 ( Figure 1E ).
pH Dependent Hemolytic Activity of RALA mRNA Nanocomplexes Enables mRNA Expression
The most appealing property of RALA is its capacity to selectively disrupt membranes at acidic pH. This feature is illustrated in Figure 2A , showing RALA-induced hemolysis of chicken red blood cells (RBC) at neutral pH (pH 7.4) and at acidic pH (pH 5.6). To address whether this critical feature of RALA is retained upon mRNA binding, we performed an identical hemolysis assay, using mRNA complexed RALA. While little hemolysis was evident at N/P 1, RALA mRNA nanocomplexes did instigate significant hemolysis at N/P 5 and especially at N/P 10 ( Figure 2B ). Furthermore, levels of hemolysis were strongly elevated by lowering the pH, thereby demonstrating that RALA indeed retains its pH dependent membrane disruptive properties even when complexed into mRNA nanocomplexes. To further verify to what extent this membrane disruptive feature of RALA mRNA complexes may enable mRNA expression inside DCs, we complexed mRNA encoding enhanced Green Fluorescent Protein (eGFP) into RALA mRNA nanocomplexes. DC2.4 cells were incubated with free mRNA or with RALA mRNA nanocomplexes at, respectively, N/P 1, N/P 5, and N/P 10 for 4 h. The amount of mRNA delivered was kept constant in these experiments. Flow cytometric analysis revealed no eGFP expression upon incubation of DC2.4 cells with free mRNA or with RALA mRNA nanocomplexes at N/P 1 -at which we demonstrated most mRNA to be in a free, noncomplexed status. Conversely, RALA mRNA nanocomplexes supported eGFP expression in ≈35% of all cells at N/P 5 and at N/P 10 ( Figure 2C ). Promoting endosomal disruption by addition of chloroquine -an endosomal disrupting agent did not significantly augment the transfection efficiency of the RALA mRNA nanocomplexes ( Figure 2D ). This indicates that RALA by itself is fully competent to translocate its mRNA cargo to the cytosol.
RALA mRNA Nanocomplexes Support Antigen-Specific CD8 T Cell Proliferation
To determine the capacity of RALA mRNA nanocomplexes to prime CD8+ T cells, an OT-I proliferation assay was performed. C57BL6 mice were immunized with RALA complexed to mRNA encoding the model antigen ovalbumin (OVA) and T cell priming was assessed by flow cytometric quantification of the proliferation of CD8+ OT-I T cells. An overview of the flow cytometry gating strategy is given in Figure S1 (Supporting Information). Figure 3A shows the flow cytometry plots and Figure 3B the percentages of OT-I T cells that have divided upon immunization with free mRNA or mRNA complexed with RALA at N/P 1, N/P 5, and N/P 10. No antigen-specific T cell proliferation was observed upon immunization with free mRNA or RALA complexed mRNA at N/P 1, whereas immunization with N/P 5 and N/P 10 mRNA RALA nanocomplexes elicited significant OVA-specific T cell proliferation. 
Incorporation of Pseudouridine and 5-Methylcytidine Nucleosides into RALA Delivered mRNA Enhances mRNA Expression Levels but Reduces DC Activation
The incorporation of the modified nucleosides pseudouridine and 5-methylcytidine into mRNA has been reported to enhance mRNA expression levels by lowering the activation of protein kinase R. [10] To address the impact of pseudouridine and 5-methylcytidine modified mRNA (hereafter named modified mRNA) on the expression levels of RALA delivered mRNA, we transfected bone marrow derived DCs with, respectively, unmodified mRNA or modified mRNA (encoding eGFP) complexed to RALA at N/P 10. eGFP expression levels were quantified by flow cytometry. As can be appreciated from Figure 4B , DCs incubated with modified mRNA complexed to RALA showed significantly higher expression levels compared to DCs transfected with unmodified mRNA complexed to RALA.
The use of modified mRNA has been demonstrated to reduce mRNA recognition by pathogen recognition receptors and hence to decrease innate immune activation. Activation of DCs constitutes a crucial prerequisite to initiate T cell responses. We thus assessed the impact of RALA delivered mRNA on the activation status of DCs by flow cytometry ( Figure 4C ) and by inflammatory cytokine secretion ( Figure 4D ). Uptake of noncomplexed mRNA is highly inefficient in vitro and did not promote DC activation, regardless of the mRNA format. Upon complexation to RALA (N/P 10), unmodified mRNA induced a strong upregulation of CD40, CD86, and MHCII. In line with its described lower capacity to trigger RNA sensors, modified mRNA complexed to RALA was less potent in activating DCs, but surface levels of CD40, MHCII, and CD86 were still increased compared to PBS treated DCs. DCs incubated with unmodified mRNA complexed to RALA displayed a pronounced upregulation of IFN-β expression and -albeit to a lower extent -of IL-6 expression. Incorporation of modified mRNA into RALA mRNA nanocomplexes strongly reduced IFN-β production. Conversely, the use of modified mRNA did not decrease IL-6 expression. Similar results have been reported by Kariko et al., [11] who demonstrated that incubation of DCs with modified mRNA reduced IFN-β production while leaving TNF-α production unaffected.
Modified mRNA Is Superior to Nonmodified mRNA in Instigating In Vivo T Cell Immunity to RALA Complexed mRNA
To determine the optimal mRNA format in case of RALA-mediated mRNA vaccination, we compared the T cell response elicited by immunization with unmodified mRNA or modified mRNA complexed to RALA. In these experiments, N/P 10 was selected as this N/P ratio allowed the best complexation of mRNA and enabled efficient CD8+ T cell priming. Priming of vaccine specific T cell responses was analyzed by quantifying OT-I T cell proliferation. Representative flow cytometry plots are given in Figure 5A . Figure 5B shows the percentages and Figure 5C the total number of OT-I T cells having divided over four times. From these data, it is clear that when complexed to RALA, modified OVA mRNA is far superior in eliciting OT-I T cell proliferation compared to unmodified mRNA.
To determine whether the increased T cell proliferation following immunization also resulted in the differentiation of antigen-experienced T cells into cytolytic effectors, an in vivo killing assay was performed. In such assay, immunized mice are challenged with a 1/1 ratio of differentially CFSE labeled target cells and nontarget cells. Two days after challenge, the www.advancedsciencenews.com www.advhealthmat.de ratio of both populations represents a direct measure of the antigen-specific cytolytic T cell activity. Vaccination with RALAcomplexed modified OVA mRNA killed virtually all target cells, whereas no target cell killing was observed upon vaccination with RALA-complexed unmodified OVA mRNA ( Figure 5D ,E). This higher immunogenicity of modified mRNA over unmodified mRNA is remarkable as modified mRNAs have been developed by the gene therapy field exactly to avoid immune responses against the encoded protein. [11] To address whether the improvement in T cell immunity conveyed by the use of modified mRNA represents a common feature of mRNA nanocomplexes upon intradermal vaccination, we performed a direct comparison with a conventional lipoplex (1,2-dioleoyl-3-trimethylammonium-propane (DOTAP)/1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE))-based mRNA vaccine, the current benchmark mRNA lipoplex formulation evaluated in clinical trials. [4b] mRNA lipoplexes were used at N/P 1, which we recently demonstrated to be the optimal ratio for intradermal and subcutaneous mRNA lipoplex vaccination. [4a,12] At this N/P ratio, mRNA lipoplexes typically possess a negative surface charge and contain an excess of noncomplexed mRNA. At N/P10, DOTAP/DOPE mRNA lipoplexes instead encapsulate most of the mRNA, are cationic in charge, but fail to elicit T cell responses in vivo. A similar low N/P ratio (1.7/2) was identified by Sahin and co-workers [4b] to be optimal for intravenous vaccination with DOTAP/DOPE mRNA lipoplexes. In sharp contrast to RALA mediated mRNA vaccination, lipoplex mediated vaccination however did not benefit from the use of modified mRNA ( Figure 5E ), thus demonstrating that the regulation of T cell immunity to mRNA vaccines is heavily influenced by the delivery system applied.
Type I IFN Regulate T Cell Immunity to RALA Based Immunization
Earlier, we demonstrated that type I IFN negatively regulate T cell immunity to subcutaneous and intradermal vaccination with DOTAP/DOPE mRNA lipoplexes. [4a,12] To address whether this feature also holds true for RALA mRNA nanocomplexes, we compared cytolytic T cell responses between wild type (WT) mice and mice lacking the common IFN-α/β receptor (Ifnar To obtain a better insight into the differential outcome of immunization with modified mRNA complexed to, respectively, RALA (improvement) or DOTAP/DOPE (no effect), we monitored IFN-β induction in an IFN-β reporter mouse strain, in which expression of firefly luciferase is driven by the IFN-β promoter. [13] In vivo bioluminescence imaging revealed a vast IFN-β response upon intradermal injection of noncomplexed modified mRNA or modified mRNA containing lipoplexes (N/P 1). Consequently, modified mRNA does not succeed in dampening the negative effects of type I IFN on T cell immunity in the context of mRNA lipoplex vaccination, which explains the strong improvement of T cell immunity upon immunization of Ifnar −/− mice with modified mRNA containing lipoplexes ( Figure 6B ). Upon complexation to RALA, modified mRNA instead hardly provokes a IFN-β response and thus avoided the negative impact of type I IFN ( Figure 6E ). Hence, no further increase in T cell immunity was observed in Ifnar −/− mice upon immunization with modified mRNA RALA nanocomplexes ( Figure 6A ).
Nonamphipathic Cationic Peptide Variants: Characterization of Peptide mRNA Nanocomplexes
Having established the capacity of RALA to efficiently deliver an antigenic mRNA cargo to the immune system, we aimed to 
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by a hydrophilic RGSG motif. In the second peptide (named RRRR hereafter), the hydrophobic alanine and leucine residues of RALA were omitted. Peptide sequences and predicted peptide secondary structures are depicted in Figure 7A . Both peptides lack RALA's amphipathic α-helical structure as they do not contain hydrophobic residues. RGSG has a random-coil www.advancedsciencenews.com www.advhealthmat.de like structure, while RRRR forms a short α-helical structure to minimize electrostatic repulsion between the adjacent cationic arginine residues. First, we assessed the impact of these sequence modifications on the capacity of the respective peptides to disrupt membranes by performing a hemolysis assay. Disturbance of the RALA motif abrogated hemolytic activity, with RGSG and RRRR clearly failing to lyse RBCs regardless of pH ( Figure 7B ). Yet, due to their cationic arginine residues, RGSG and RRRR were still capable of condensing the mRNA into nanocomplexes. However, when compared to RALA, the dimensions of RGSG and RRRR mRNA nanocomplexes were strongly influenced by the N/P ratio applied ( Figure 7C ). Particle size for RGSG-modified mRNA nanocomplexes peaked to around 600 nm at N/P 5 and subsequently declined to 150 nm at N/P 10. In case of RRRR-modified mRNA nanocomplexes, particle sizes ranged from 140 nm at N/P 1 over 200 nm at N/P 5 up to 1050 nm at N/P 10. RGSG and RRRR -modified mRNA nanocomplexes also showed a different surface charge evolution with increasing N/P ratios. Whereas RALA mRNA nanocomplexes robustly shifted their ζ-potential from negative to positive values at higher N/P ratios, the shift in ζ-potential was far less pronounced for RGSG and RRRR mRNA nanocomplexes ( Figure 7D ). Instead, RGSG-modified mRNA nanocomplexes adopted a near neutral charge at N/P 5 and at N/P 10, whereas RRRR-modified mRNA nanocomplexes remained negatively charged even at N/P 10.
Finally, in order to compare the capacities of RALA, RGSG, and RRRR to encapsulate modified mRNA into nanocomplexes, we measured the amount of nonencapsulated mRNA ( Figure 7E ). Also here, RALA was far more efficient at encapsulating mRNA even at the low N/P 1 ratio. At N/P 5, RGSG encapsulated 72.5% of the added mRNA, whereas RRRR still encapsulated a mere 10% at this N/P ratio. However, at N/P 10, all peptides succeeded in encapsulating over 75% of the added mRNA. Consequently, N/P 10 was selected for all subsequent experiments.
Lack of Immunogenicity of RGSG and RRRR mRNA Nanocomplexes
To verify whether RSGS and RRRR would retain RALA's capacity to prime CD8+ T cell responses against the mRNA encoded antigen, we complexed modified OVA-encoding mRNA with the respective peptides. All nanocomplexes were generated at a ratio of N/P 10 as this ratio was most efficient in mRNA complexation for RGSG and RRRR as well as for RALA. The priming activity of the mRNA nanocomplexes was assayed on the basis of the in vivo proliferation of adoptively transferred CD8+ OT-I T cells as before. RGSG and RRRR OVA mRNA nanocomplexes failed to prime substantial CD8+ T cell responses (Figure 8A) , thereby indicating that RALA has unique features that mediate its effectiveness as a carrier for mRNA vaccination. To address whether the failure of RGSG and RRRR mRNA nanocomplexes to elicit CD8+ T cell reactivity might be traced back to an insufficient antigen expression in DCs, we coincubated DC2.4 dendritic cells with modified eGFP mRNA complexed to either RALA, RGSG, or RRRR. The results from flow cytometry ( Figure 8B ) confirm the efficacy of RALA-based transfection, and simultaneously unveil the failure of RGSG and RRRR mRNA nanocomplexes to enable eGFP expression in DC2.4 cells. The differential capacities of RALA, RGSG, and RRRR to transfect cells and to prime CD8 + T cell responses in vivo might reflect a differential uptake of the mRNA nanocomplexes and/or a differential capacity of the peptides to facilitate mRNA escape to the cytosol after endocytosis. In order to verify the uptake and intracellular fate of the mRNA cargo, mRNA was fluorescently labeled with Cy3b. Flow cytometric analysis showed significant differences in the percentages of DC2.4 DCs that had bound and/or internalized the respective peptide mRNA nanocomplexes ( Figure S2a , Supporting Information). Whereas 72% of DC2.4 cells stained Cy3b positive Figure 7 . Characterization of RGSG and RRRR based mRNA nanocomplexes. A) Sequences and secondary structures of RALA, RGSG, and RRRR peptides, based on the de novo PEP-FOLD peptide prediction server. Arginine residues (R) are shown in blue, leucine and alanine residues in red, serine and glycine in green. B) Graph depicting the hemolytic activity of equivalent amounts of RALA, RGSG, and RRRR at pH 7.4 and at pH 5.6. C) Hydrodynamic diameter (nm) of RALA, RGSG, and RRRR peptide mRNA nanocomplexes at the indicated N/P ratios. D) ζ-potential of RALA, RGSG, and RRRR peptide mRNA nanocomplexes at the indicated N/P ratios. E) Encapsulation efficiencies of mRNA into, respectively, RALA, RGSG, and RRRR mRNA nanocomplexes as a function of the indicated N/P ratios. The percentage mRNA encapsulated was calculated as 100% − %free mRNA. Measurements are shown as mean (n = 3) ± SD. after incubation with RALA Cy3b mRNA, this percentage dropped to a mere 7% for RGSG Cy3b mRNA and an intermediate 52% for RRRR Cy3b mRNA. Analysis of the mean fluorescence intensity revealed a similar trend with RALA enabling the strongest mRNA uptake, RGSG the lowest, and RRRR an intermediate ( Figure S2b , Supporting Information).
To quantify to what extent the RALA, RGSG, and RRRR peptides facilitated endosomal escape of their mRNA cargo, Mander's colocalization coefficient was calculated for colocalization of macropinosomes (ARF6), clathrin coated vesicles (clathrin light chain) or caveolae (caveolin) and mRNA nanocomplexes ( Figure 8C,D) . Only in the case of RALA-mediated mRNA delivery, we could detect mRNA inside DC2.4 cells that did not colocalize with any of these vesicular markers. Conversely, mRNA delivered by RRRR and RGSG always colocalized with at least one of the vesicular markers applied. These data indicate that RALA mRNA nanocomplexes enable endosomal escape of the antigen mRNA, in contrast to RGSG and RRRR-delivered mRNA, which appears to remain trapped inside endocytic vesicles.
Discussion
CPPs have been widely explored in the context of siRNA and of pDNA delivery but have remained remarkably unexplored in the context of mRNA delivery. Here, we describe the use of the cationic, amphipathic CPP RALA to successfully deliver antigen-encoding mRNA to the immune system. We showed that RALA-based mRNA delivery stimulated mRNA uptake by DCs and facilitated mRNA release from the endosomes to the cytosol, resulting in efficient antigen expression inside the DC. This capacity of RALA to instigate T cell immunity was strongly sequence dependent, as removal of the hydrophobic alanine and leucine residues or replacement by hydrophilic glycine and serine residues also abrogated the peptide's immune-potentiating properties. Nanocomplexes of mRNA with arginine-rich peptide variants that lack the RALA motif showed reduced mRNA encapsulation efficiency and impaired DC uptake. Moreover, those mRNA nanocomplexes that were internalized remained entrapped in endosomal vesicles. As a consequence, these peptide variants failed to support the expression of the mRNA-encoded antigen that is required to prime T cell responses. In addition to a thorough assessment of the crucial features that determine the immunogenicity of RALA mRNA nanocomplexes at the peptide level, we also determined the impact of the mRNA format on the strength of the evoked T cell response at the mRNA level. In combination with RALA, 5-methylcytidine and pseudouridine modified mRNA proved to be superior to nonmodified mRNA in eliciting cytolytic T cell responses. The beneficial outcome of modified mRNA on T cell immunity is striking, as these mRNA modifications have been developed exactly to reduce innate immune activation in the context of gene replacement therapy. Our data strongly indicate that this phenomenon can be explained by the reduced type I IFN response generated, yielded upon the use of modified mRNA. Earlier, we demonstrated that type I IFN have a negative impact on the efficacy of mRNA lipoplexes to instigate T cell response upon intradermal vaccination with DOTAP/DOPE mRNA lipoplexes. [4a,12a] Much alike, T cell immunity to RALA mRNA nanocomplexes comprising nonmodified suffered from the induction of type I IFN responses, as mice lacking IFNAR showed improved T cell responses to vaccination. Usage of modified mRNA in combination with RALA reduced the type I IFN response to such extent their block on T cell responses was relieved. The near-complete complexation of mRNA to RALA was of paramount importance in this respect, as the incomplete complexation of mRNA in case of DOTAP/DOPE mRNA lipoplexes failed to sufficiently reduce the type I IFN response to avoid its negative impact on the T cell immunity.
Conclusion
We have demonstrated the high potential of RALA in complexing antigen-encoding mRNA into highly immunogenic nanocomplexes. In terms of potency, RALA-mediated mRNA vaccination clearly outperformed a standard liposomal mRNA formulation composed of the cationic lipid DOTAP and the fusogenic lipid DOPE. Based on this combination of high immunogenicity and ease-of-production, we believe that RALA -and by extension other CPPs -constitute highly promising delivery vehicles for mRNA vaccines that merit further study.
Experimental Section
Animals: Female wild type C57BL/6 mice were purchased from Janvier (Le Genest Saint Isle, France). OT-I mice carrying a transgenic CD8 + T cell receptor specific for the MHC I-restricted OVA peptide SIINFEKL were donated by Dr. Bart Lambrecht from the Ghent University (Ghent, Belgium). Ifnar1 −/− mice were bred at the breeding facility of the Vlaams Instituut voor Biotechnologie (Ghent, Belgium). C57BL/6 luciferase reporter mice (IFN-β +/Δβ-luc ) were bred at the Helmholtz Centre for Infection Research. All mice were 7-12 weeks old at the start of the experiment and maintained under specific pathogen-free conditions. Animals were treated according to the European guidelines for animal experimentation. All experiments were approved by the local ethical committee for animal experiments of the Ghent University (Ghent, Belgium) or of the Helmholtz Center for Infection Research (Braunschweig, Germany).
Nanoparticle Preparation: RALA was produced by solid-state synthesis and supplied as an acetate salt lyophilized powder (Biomatik, USA). eGFP mRNA (unmod: L-6301; mod: L-6303) and ovalbumin mRNA (unmod: L-6326; mod: L-6128) were purchased from TriLink BioTechnologies (San Diego, USA). RALA/mRNA complexes were prepared at N/P ratios 1, 5, and 10 by adding appropriate volumes of RALA peptide solution to a specific amount of mRNA. The N/P ratio represents the molar ratio of positively charged nitrogen atoms in the peptide to negatively charged phosphates in the mRNA backbone. For lipid-based complexation of mRNA cationic lipid, DOTAP and DOPE were added to the mRNA at N/P ratio 1 (both Avanti Polar Lipids, Alabaster, AL, USA).
Nanoparticle Characterization: For size and zeta potential measurements, particles were analyzed using a Nano ZS Zetasizer (Malvern Instruments, UK). The shape and surface morphology were observed using Jeol JEM1400plus transmission electron microscope at 30 kV.
Encapsulation Assay: Quant-iT RNA assay kit (Life Technologies, UK) was diluted 1:200 in TAE buffer and added to an equal volume of nanoparticle prepared solution. Sample fluorescence was analyzed using a Synergy 2 Multi-Mode Microplate Reader (BioTek Instruments Inc., UK).
Hemolysis Assay: Chicken RBCs (Veterinary department, UGent) were resuspended in pH 5.6 and pH 7.4 buffer solutions separately. The cell
